glp 1 iih GLP-1 Agonists May Help Reduce Use of Acetazolamide in IIH (Idiopathic Intracranial Hypertension): Symptoms,

Asia-Pacific is projected to host the fastest-growing GLP-1 receptor agonist market in the coming years

The GLP-1 mechanism of action also explains why results accelerate over time rather than plateauing immediately like most diets

The FDA ended shortage-related compounding in 2025 and, on April 30, 2026, proposed keeping tirzepatide off the 503B bulks list permanently

Holscher HD, Taylor AM, Swanson KS, Novotny JA, Baer DJ

Randomized controlled trial (RCT) evidence is limited and not yet definitive for prevention

The choice between oral GLP-1 and injectable therapy is quickly becoming a central question in type 2 diabetes care